Market Cap | 25.81M | P/E | - | EPS this Y | -162.50% | Ern Qtrly Grth | - |
Income | -13.34M | Forward P/E | -0.95 | EPS next Y | 214.30% | 50D Avg Chg | 1.00% |
Sales | 36.08M | PEG | - | EPS past 5Y | 24.21% | 200D Avg Chg | -25.00% |
Dividend | N/A | Price/Book | 0.88 | EPS next 5Y | - | 52W High Chg | -77.00% |
Recommedations | 2.00 | Quick Ratio | 1.71 | Shares Outstanding | 35.25M | 52W Low Chg | 56.00% |
Insider Own | 36.42% | ROA | -14.08% | Shares Float | 17.76M | Beta | 1.67 |
Inst Own | 21.57% | ROE | -48.92% | Shares Shorted/Prior | 396.87K/408.90K | Price | 0.75 |
Gross Margin | 100.00% | Profit Margin | -36.96% | Avg. Volume | 193,314 | Target Price | - |
Oper. Margin | -34.74% | Earnings Date | May 9 | Volume | 2,867,938 | Change | 2.70% |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
HC Wainwright & Co. | Buy | Apr 2, 24 |
HC Wainwright & Co. | Buy | Dec 26, 23 |
HC Wainwright & Co. | Buy | Nov 13, 23 |
Cantor Fitzgerald | Overweight | Aug 14, 23 |
HC Wainwright & Co. | Buy | Aug 14, 23 |
HC Wainwright & Co. | Buy | May 15, 23 |
HC Wainwright & Co. | Buy | May 1, 23 |
Stifel | Buy | Mar 24, 23 |
SVB Leerink | Outperform | Feb 8, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Keyes Jason A | Chief Financial Offi.. Chief Financial Officer | Aug 29 | Sell | 2.83 | 7,000 | 19,810 | 77,720 | 08/30/22 |
Keyes Jason A | Chief Financial Offi.. Chief Financial Officer | Jun 06 | Sell | 2.52 | 5,000 | 12,600 | 84,720 | 06/06/22 |
Keyes Jason A | Chief Financial Offi.. Chief Financial Officer | Apr 04 | Sell | 3.18 | 8,000 | 25,440 | 89,720 | 04/05/22 |
Connelly Stephen | Chief Scientific Off.. Chief Scientific Officer | Oct 06 | Option | 3.78 | 8,092 | 30,588 | 995,467 | 10/07/21 |
Connelly Stephen | Chief Scientific Off.. Chief Scientific Officer | Oct 06 | Sell | 7.01 | 8,092 | 56,725 | 993,000 | 10/07/21 |